FTC Announces Annual Update to HSR Thresholds
Client Alert | 2 min read | 01.24.24
The Federal Trade Commission announced its annual updates to the thresholds and filing fees related to the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (the HSR Act) on Monday. These dollar thresholds are indexed annually based on changes in the U.S. gross national product and the Consumer Price Index.
The HSR Act requires that certain transactions be notified prior to their consummation. This year, the “size-of-transaction" threshold for reporting mergers and acquisitions under the HSR Act will increase from $111.4 million to $119.5 million. In addition, the "size-of-person" threshold, the filing fee thresholds, and the fee schedule will all also increase. The new filing fee thresholds and fee schedule are as follows:
2024 Filing Fee |
2024 Size of Transaction |
|
$30,000 |
Less than $173.3 million |
|
$105,000 |
Not less than $173.3 million but less than $536.5 million |
|
$260,000 |
Not less than $536.5 million but less than $1.073 billion |
|
$415,000 |
Not less than $1.073 billion but less than $2.146 billion |
|
$830,000 |
Not less than $2.146 billion but less than $5.365 billion |
|
$2,335,000 |
$5.365 billion or more |
All of these revised thresholds will become effective thirty days after their publication in the Federal Register, which is expected in the next few days. Click here to read a full copy of the Commission's announcement, including a complete listing of the revised thresholds.
Contacts
Counsel
She/Her/Hers
Insights
Client Alert | 4 min read | 08.29.25
Gender-Affirming Care Targeted for Potential False Claims Act Enforcement
On August 19, 2025, the Office of Personnel Management (OPM) informed insurers participating in the Federal Employees Health Benefits or Postal Service Health Benefits programs that gender-affirming care would no longer be covered for federal workers starting in 2026. This coverage decision is the Trump Administration’s latest action stemming from Executive Order 14187 which aims to prevent certain treatments, such as gender-affirming hormone therapy, surgeries, and puberty blockers for those under the age of 19. As previously discussed, the Administration has also signaled its intent to use various law enforcement tools against gender-affirming care, including Section 5 of the Federal Trade Commission Act to police false or unsupported claims by medical professionals about gender-affirming treatments.
Client Alert | 4 min read | 08.28.25
9th Circuit Marches Forward to the Future Finding Digital Assets Are Protected Under Trademark Law
Client Alert | 2 min read | 08.27.25
CPSC Maintains Momentum on eFiling Requirements for Consumer Products
Client Alert | 10 min read | 08.27.25
The New EU “Pharma Package”: Advertising – A Comparison of Commission/Parliament/Council Positions
